Stepping Beyond the Status Quo in Heart Failure: The Revolutionary Role of SGLT2 Inhibition

June 15, 2021

This Grand Rounds initiative is targeted to cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants. Designed to foster meaningful interprofessional and interdisciplinary collaboration, this accredited activity will explore the evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs), as well as evaluate foundational mechanisms linking type 2 diabetes (T2D) to heart failure (HF). Expert faculty will also examine new and emerging CVOT data for SGLT2 inhibitors, including recent approvals and guideline recommendations, and offer insights into how these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients. To reinforce these teaching points within the context of a collaborative approach, attendees will be engaged in a case-based discussion focused on key characteristics of an effective, integrated approach to HF management.

Target Audience

Cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants, focused on the integration of new and emerging CVOT data into clinical practice, with an emphasis on collaborative management of heart failure.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Explore the evolution of SGLT2 inhibition in the CVOT era and evaluate mechanisms linking T2D and heart failure (HF).
  • Appraise new and emerging CVOT data for antihyperglycemic agents and compare outcomes data across the type 2 diabetes (T2D) therapeutic classes.
  • Examine recently-reported CVOT data for SGLT2 inhibitors, and discuss ways that these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients.
  • Using a case-based format, recognize opportunities for cardiologists to collaborate with endocrinologists, primary care providers, and other members of the healthcare team, and identify key characteristics of an integrated approach to HF management.
Course summary
Available credit: 
  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 ICPE
  • 1.00 Participation
Course opens: 
04/30/2021
Course expires: 
07/15/2021
Event starts: 
06/15/2021 - 6:30pm
Event ends: 
06/15/2021 - 7:30pm
Rating: 
0
Live Virtual Event
Kentucky Community Grand Rounds
United States

Kim Birtcher, MS, PharmD
Clinical Professor
University of Houston College of Pharmacy
Houston, Texas

 


Kim K. Birtcher is a Clinical Professor at the University of Houston College of Pharmacy. She is also a clinical pharmacist in Kelsey-Seybold Clinic’s Cardiology Clinic in Houston, Texas, where she is responsible for the Secondary Prevention Lipid Clinic. Her teaching and research interests are in cardiovascular risk reduction and quality improvement initiatives.

Dr. Birtcher received her BS in Pharmacy and MS in Pharmacy Administration from the University of Texas at Austin. She received her Doctor of Pharmacy from the University of Florida. Dr. Birtcher is a Board Certified pharmacotherapy specialist with additional qualifications in cardiology, a certified diabetes educator, and a clinical lipid specialist. She is an Associate of the American College of Cardiology and a fellow of the National Lipid Association.

Dr. Birtcher is an active member in the American College of Cardiology, serving on several task forces and committees. She is a member of the Task Force On Clinical Practice Guidelines and the past Co-Chair, LDL Address the Risk Initiative.
 


Planner and Faculty Disclosures

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

PLANNERS:
Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Javed Butler, MD, MPH, MBA–has disclosed that he is a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, and Vifor.
Muthiah Vaduganathan, MD, MPH–has disclosed that he is a consultant for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, and Relypsa and receives grant/research support from KL2/Catalyst Medical Research Investigator Training.

PRESENTERS:
Jarett Berry, MD- has disclosed that he is a consultant for AstraZeneca and Roche; he also receives grant/research support from Abbott, NIH, and Roche.
Kim Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE, CLS–has no relevant financial relationships to disclose in relation to the content of this activity.
Javed Butler, MD, MPH, MBA–has disclosed that he is a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, and Vifor.
Muthiah Vaduganathan, MD, MPH–has disclosed that he is a consultant for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, and Relypsa and receives grant/research support from KL2/Catalyst Medical Research Investigator Training.

PEER REVIEWERS:
Kim Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE, CLS–has no relevant financial relationships to disclose in relation to the content of this activity.
Debra K. Moser, PhD, RN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.
Ambarish Pandey, MD, MSCS–has no relevant financial relationships to disclose in relation to the content of this activity.
Scott Urquhart, PA-C, DFAAPA–has disclosed that he is a consultant for AstraZeneca, Dexcom, Novo Nordisk. and Sanofi. He is a member of the speakers' bureau for AstraZeneca and Novo Nordisk.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

ICPE

This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.

Medicine (ACCME)

CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)

This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-008-L01-P).

Nursing (ANCC)

This activity is designated for 1.0 contact hour.

Physician Assistants (AAPA)

Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.

Available Credit

  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 ICPE
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

Ashley Lilly is inviting you to a scheduled Zoom meeting.

Topic: Stepping Beyond Grand Rounds
Time: Dec 9, 2020 12:00 PM Eastern Time (US and Canada)

Join Zoom Meeting:
https://zoom.us/j/96920237653?pwd=anNlWmZKdTN1dmtMaWJPSzR0NDdzZz09

Meeting ID: 969 2023 7653
Passcode: 630970
One tap mobile
+13017158592,,94850094120# US (Germantown)
+13126266799,,94850094120# US (Chicago)

Dial by your location
        +1 301 715 8592 US (Germantown)
        +1 312 626 6799 US (Chicago)
        +1 646 558 8656 US (New York)
        +1 253 215 8782 US (Tacoma)
        +1 346 248 7799 US (Houston)
        +1 669 900 9128 US (San Jose)
Meeting ID: 969 2023 7653
Find your local number: https://zoom.us/u/abk7lQBK9r